These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32737019)

  • 1. Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - Literature review.
    Ferreira LM; Cerezer JL; Gehrcke M
    Hematol Transfus Cell Ther; 2021; 43(2):185-190. PubMed ID: 32737019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma.
    Lavi N; Okasha D; Sabo E; Oren I; Benyamini N; Bar-Yoseph H
    Eur J Haematol; 2018 Aug; ():. PubMed ID: 30120798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
    van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
    Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
    Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
    Nijhof IS; Casneuf T; van Velzen J; van Kessel B; Axel AE; Syed K; Groen RW; van Duin M; Sonneveld P; Minnema MC; Zweegman S; Chiu C; Bloem AC; Mutis T; Lokhorst HM; Sasser AK; van de Donk NW
    Blood; 2016 Aug; 128(7):959-70. PubMed ID: 27307294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.
    Frerichs KA; Bosman PWC; Nijhof IS; Zweegman S; van de Donk NWCJ
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e9-e11. PubMed ID: 30392824
    [No Abstract]   [Full Text] [Related]  

  • 7. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Plesner T; van de Donk N; Richardson PG
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
    Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K
    Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
    Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
    Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
    Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
    Front Oncol; 2020; 10():624661. PubMed ID: 33680948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis.
    Vassilopoulos S; Vassilopoulos A; Kalligeros M; Shehadeh F; Mylonakis E
    Open Forum Infect Dis; 2022 Nov; 9(11):ofac574. PubMed ID: 36438616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
    Pick M; Vainstein V; Goldschmidt N; Lavie D; Libster D; Gural A; Grisariu S; Avni B; Ben Yehuda D; Gatt ME
    Eur J Haematol; 2018 May; 100(5):494-501. PubMed ID: 29453884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab for the treatment of multiple myeloma.
    Goldsmith SR; Foley N; Schroeder MA
    Drugs Today (Barc); 2021 Oct; 57(10):591-605. PubMed ID: 34713868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab for the treatment of multiple myeloma.
    Touzeau C; Moreau P
    Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD38-specific nanobodies allow
    Pape LJ; Hambach J; Gebhardt AJ; Rissiek B; Stähler T; Tode N; Khan C; Weisel K; Adam G; Koch-Nolte F; Bannas P
    Front Immunol; 2022; 13():1010270. PubMed ID: 36389758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure.
    Zamanillo I; Medina de Alba L; Gil R; de la Puerta R; Alonso R; Jimenez-Ubieto A; Cedena MT; Calbacho M; Ayala R; Martinez-Lopez J
    Life (Basel); 2023 Aug; 13(9):. PubMed ID: 37763245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.